122 related articles for article (PubMed ID: 31418707)
1. [Comparison of two kits of anti-infliximab antibodies plasmatic measurement].
Charfi R; Mahmoud I; Ben Salem F; Moalla M; Bouden S; Sfar I; Saïdane O; Klouz A; Daghfous R; Gorgi Y; Abdelmoula L; Trabelsi S
Ann Biol Clin (Paris); 2019 Aug; 77(4):453-458. PubMed ID: 31418707
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
[TBL] [Abstract][Full Text] [Related]
3. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
4. Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.
Hernández-Flórez D; Valor L; de la Torre I; Nieto JC; Martínez-Estupiñán L; González C; López-Longo FJ; Monteagudo I; Garrido J; Naredo E; Carreño L
Rheumatol Int; 2015 Jun; 35(6):1021-5. PubMed ID: 25410014
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
[TBL] [Abstract][Full Text] [Related]
10. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
11. A review of six methods for monitoring infliximab concentrations and antibodies to infliximab
.
Cao F; Cao H; Cao X
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):571-580. PubMed ID: 28513424
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
[TBL] [Abstract][Full Text] [Related]
13. [THE INPUT OF MEASURING INFLIXIMAB LEVELS AND LEVELS OF ANTIBODIES TO INFLIXIMAB IN THE MANAGEMENT OF PATIENTS WITH RHEUMATIC DISEASES].
Braun-Moscovici Y; Dagan A; Toledano K; Markovits D; Saffouri A; Beshara-Garzoz R; Naffaa ME; Rozin A; Nahir MA; Balbir-Gurman A
Harefuah; 2017 Jul; 156(7):427-430. PubMed ID: 28786280
[TBL] [Abstract][Full Text] [Related]
14. Comparison of infliximab drug measurement across three commercially available ELISA kits.
Lee MW; Connor S; Ng W; Toong CM
Pathology; 2016 Oct; 48(6):608-12. PubMed ID: 27567230
[TBL] [Abstract][Full Text] [Related]
15. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
Dave MB; Dherai AJ; Desai DC; Keny BG; Shetty DN; Kulkarni S; Peddy K; Ashavaid TF
Indian J Gastroenterol; 2020 Oct; 39(5):426-434. PubMed ID: 33118097
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
19. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
20. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Dias CC; Magro F;
Aliment Pharmacol Ther; 2016 Oct; 44(7):684-92. PubMed ID: 27507790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
